These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 23200977)
1. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ; Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977 [TBL] [Abstract][Full Text] [Related]
2. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ; Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200 [TBL] [Abstract][Full Text] [Related]
3. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565 [TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. El-Serag HB; Aguirre TV; Davis S; Kuebeler M; Bhattacharyya A; Sampliner RE Am J Gastroenterol; 2004 Oct; 99(10):1877-83. PubMed ID: 15447744 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Proton Pump Inhibitors on Barrett's Esophagus. Dunbar KB; Souza RF; Spechler SJ Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202 [TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286 [TBL] [Abstract][Full Text] [Related]
7. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study. Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977 [TBL] [Abstract][Full Text] [Related]
8. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus? Akın H; Aydın Y Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164 [TBL] [Abstract][Full Text] [Related]
9. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245 [TBL] [Abstract][Full Text] [Related]
10. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728 [TBL] [Abstract][Full Text] [Related]
11. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018 [TBL] [Abstract][Full Text] [Related]
12. The Role of Acid Suppression in Barrett's Esophagus. Elias PS; Castell DO Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599 [TBL] [Abstract][Full Text] [Related]
13. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444 [TBL] [Abstract][Full Text] [Related]
14. Incidence of adenocarcinoma among patients with Barrett's esophagus. Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus. Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040 [TBL] [Abstract][Full Text] [Related]
16. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Coleman HG; Bhat S; Johnston BT; McManus D; Gavin AT; Murray LJ Gastroenterology; 2012 Feb; 142(2):233-40. PubMed ID: 22062359 [TBL] [Abstract][Full Text] [Related]
17. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Tan MC; El-Serag HB; Yu X; Thrift AP Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826 [TBL] [Abstract][Full Text] [Related]
18. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Cooper BT; Chapman W; Neumann CS; Gearty JC Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174 [TBL] [Abstract][Full Text] [Related]
19. Medical treatment of Barrett's esophagus: can it prevent cancer? Sampliner RE Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739 [TBL] [Abstract][Full Text] [Related]
20. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus. Shah SL; Dunbar K Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]